704 related articles for article (PubMed ID: 16420107)
1. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
[TBL] [Abstract][Full Text] [Related]
2. Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy.
Wade RL; Kindermann SL; Hou Q; Thase ME
J Manag Care Pharm; 2014 Jan; 20(1):76-85. PubMed ID: 24372461
[TBL] [Abstract][Full Text] [Related]
3. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK; Kruzikas DT; McLaughlin TP
J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
[TBL] [Abstract][Full Text] [Related]
4. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.
Vlahiotis A; Devine ST; Eichholz J; Kautzner A
J Manag Care Pharm; 2011 Mar; 17(2):123-32. PubMed ID: 21348545
[TBL] [Abstract][Full Text] [Related]
6. One-year costs of second-line therapies for depression.
Sullivan EM; Griffiths RI; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
J Clin Psychiatry; 2000 Apr; 61(4):290-8. PubMed ID: 10830151
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants.
Poret AW; Neslusan C; Ricci JF; Wang S; Khan ZM; Kwong JW
Value Health; 2001; 4(5):362-9. PubMed ID: 11705126
[TBL] [Abstract][Full Text] [Related]
8. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database.
Coupland CA; Dhiman P; Barton G; Morriss R; Arthur A; Sach T; Hippisley-Cox J
Health Technol Assess; 2011 Aug; 15(28):1-202, iii-iv. PubMed ID: 21810375
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders.
Stein MB; Cantrell CR; Sokol MC; Eaddy MT; Shah MB
Psychiatr Serv; 2006 May; 57(5):673-80. PubMed ID: 16675762
[TBL] [Abstract][Full Text] [Related]
10. Adherence to antidepressant treatment among privately insured patients diagnosed with depression.
Akincigil A; Bowblis JR; Levin C; Walkup JT; Jan S; Crystal S
Med Care; 2007 Apr; 45(4):363-9. PubMed ID: 17496721
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with antidepressant adherence for Medicaid-enrolled children and adolescents.
Fontanella CA; Bridge JA; Marcus SC; Campo JV
Ann Pharmacother; 2011 Jul; 45(7-8):898-909. PubMed ID: 21775691
[TBL] [Abstract][Full Text] [Related]
13. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
[TBL] [Abstract][Full Text] [Related]
14. Does the use of SSRIs reduce medical care utilization and expenditures?
Chung S
J Ment Health Policy Econ; 2005 Sep; 8(3):119-29. PubMed ID: 16278500
[TBL] [Abstract][Full Text] [Related]
15. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder.
Ta JT; Sullivan SD; Tung A; Oliveri D; Gillard P; Devine B
J Manag Care Spec Pharm; 2021 Feb; 27(2):223-239. PubMed ID: 33506730
[No Abstract] [Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. Improving medication management of depression in health plans.
Horgan CM; Merrick EL; Stewart MT; Scholle SH; Shih S
Psychiatr Serv; 2008 Jan; 59(1):72-7. PubMed ID: 18182542
[TBL] [Abstract][Full Text] [Related]
18. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
Griffiths RI; Sullivan EM; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
[TBL] [Abstract][Full Text] [Related]
19. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy--results from a managed care administrative claims database.
Eaddy MT; Druss BG; Sarnes MW; Regan TS; Frankum LE
J Manag Care Pharm; 2005 Mar; 11(2):145-50. PubMed ID: 15766321
[TBL] [Abstract][Full Text] [Related]
20. Measuring antidepressant prescribing practice in a health care system using administrative data: implications for quality measurement and improvement.
Kerr EA; McGlynn EA; Van Vorst KA; Wickstrom SL
Jt Comm J Qual Improv; 2000 Apr; 26(4):203-16. PubMed ID: 10749005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
